Logos Global Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Logos Global Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$84.4M	Buy	2,125,000 +1,925,000	+963%	+$49.2M	4.21%	5
2025 Q4	$5M	Sell	200,000 -325,000	-62%	-$8.23M	0.3%	54
2025 Q3	$12.7M	Buy	+525,000	New	+$9.33M	1.14%	33
2022 Q4	–	Sell	-399,801	Closed	-$1.61M	–	44
2022 Q3	$1.61M	Hold	399,801	–	–	0.2%	32
2022 Q2	$1.95M	Sell	399,801 -54,744	-12%	-$350K	0.36%	21
2022 Q1	$4.08M	Hold	454,545	–	–	0.53%	27
2021 Q4	$5.12M	Sell	454,545 -615,000	-58%	-$8.27M	0.53%	41
2021 Q3	$17.9M	Buy	1,069,545 +130,000	+14%	+$2.69M	1.29%	24
2021 Q2	$20.9M	Buy	+939,545	New	+$22.1M	1.75%	22

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Logos Global Management's CNTA Position: Q1 2026 in Review

Logos Global Management increased its Centessa Pharmaceuticals (CNTA) stake by 963% in Q1 2026, buying an estimated $49.2M and bringing the position to 2,125,000 shares worth $84.4M. The position accounts for 4.21% of the portfolio, ranked #5.

Logos Global Management first reported a position in CNTA in Q2 2021 and has held it in 9 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

Logos Global Management held 2,125,000 shares of Centessa Pharmaceuticals worth $84.4M as of Q1 2026.
Logos Global Management bought 1,925,000 Centessa Pharmaceuticals shares in Q1 2026, an estimated $49.2M.
Centessa Pharmaceuticals made up 4.21% of Logos Global Management's portfolio in Q1 2026, its #5 holding.
Logos Global Management first reported a position in Centessa Pharmaceuticals in Q2 2021 and has held it in 9 quarters since.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Logos Global Management's 13F filing for Q1 2026, filed 15 May 2026.